A. A. Neklyudov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. A. Neklyudov has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Marina V. Zavyalova
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia
3 shared publications - A. V. Zavyalov
Siberian State Medical University
2 shared publications - Sergey Viktorovich Miller
Tomsk National Research Medical Center
2 shared publications - Vladimir M. Perelmuter
Cancer Research institute, Тomsk National Research Medical Center, Russian Academy of Sciences
2 shared publications - Письменный Дмитрий Сергеевич
Cancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences; Siberian State Medical University
2 shared publications - A. V. Zavyalov
Siberian State Medical University, Tomsk
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 25 (3) , 135-145
Lymphangitic Carcinomatosis: Clinical and Morphological Manifestations and Possible Molecular Mechanisms of Development
Lymphangitic carcinomatosis is one of the most severe forms of tumor progression. It is characterized by the massive spread of tumor emboli, composed of cells with reduced adhesive capacity to the endothelium, through the lymphatic vessels. Using the PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) guidelines, 394 scientific papers were screened. Of those, 292 English-language publications met the criteria for analysis. A total of 39 articles (including three in Russian) relevant to the topic of this review were included. Due to the highly diverse localization of lymphangitic carcinomatosis and its polymorphic symptoms, diagnosis remains challenging and is associated with the risk of erroneous and often delayed decision-making. Data on lymphangitic carcinomatosis are still scarce, and its developmental mechanisms are not fully understood. However, systematizing knowledge about its possible clinical and morphological manifestations and studying the molecular and genetic mechanisms of its development could serve as a basis for identifying key prognostic markers and developing targeted therapies for this currently prognostically unfavorable form of tumor progression.
- 1 October 2026
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 25 (3) , 135-145
Open AccessLymphangitic Carcinomatosis: Clinical and Morphological Manifestations and Possible Molecular Mechanisms of Development
Lymphangitic carcinomatosis is one of the most severe forms of tumor progression. It is characterized by the massive spread of tumor emboli, composed of cells with reduced adhesive capacity to the endothelium, through the lymphatic vessels. Using the PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) guidelines, 394 scientific papers were screened. Of those, 292 English-language publications met the criteria for analysis. A total of 39 articles (including three in Russian) relevant to the topic of this review were included. Due to the highly diverse localization of lymphangitic carcinomatosis and its polymorphic symptoms, diagnosis remains challenging and is associated with the risk of erroneous and often delayed decision-making. Data on lymphangitic carcinomatosis are still scarce, and its developmental mechanisms are not fully understood. However, systematizing knowledge about its possible clinical and morphological manifestations and studying the molecular and genetic mechanisms of its development could serve as a basis for identifying key prognostic markers and developing targeted therapies for this currently prognostically unfavorable form of tumor progression.
- Open Access
- 23 July 2026
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 25 (2) , 139-149
Molecular and genetic parameters of prognosis and new strategies for the treatment of peritoneal carcinomatosis in gastric cancer
Despite advances in modern oncology, in Russia, 36% of gastric cancers are detected at an advanced stage, with a one-year mortality rate of 39.6%. One of the most common causes of death from gastric cancer is peritoneal carcinomatosis. Synchronous peritoneal carcinomatosis is diagnosed in 18–26% of cases. Metachronous carcinomatosis occurs in 7–39% of patients 8.5–26 months after the primary tumor is removed. To date, there are no effective treatments for peritoneal carcinomatosis. Tumors accompanied by peritoneal carcinomatosis are often resistant to systemic chemotherapy. Cytoreductive surgeries and intraperitoneal chemotherapy are not always possible or successful for all patients.This review focuses on analyzing the molecular and genetic mechanisms of peritoneal carcinomatosis in gastric cancer and presents an original hypothesis suggesting that peritoneal carcinomatosis occurs when tumor cells acquire the ability to autonomously exist in a matrix-independent state in the ascitic fluid without undergoing apoptosis (anoeucsis). Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, 10,025 scientific papers were identified, of which 228 English-language and 323 Russian-language publications met the analysis criteria. Twenty-nine articles (including four Russian-language ones) relevant to the topic of this review were included in the review. It is assumed that the identification of key molecules associated with the matrixindependent existence of tumor cells could serve as the basis for the development of technologies for predicting peritoneal carcinomatosis, as well as for the development of new targeted therapy for metastatic gastric cancer.
- 23 July 2026
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 25 (2) , 139-149
Open AccessMolecular and genetic parameters of prognosis and new strategies for the treatment of peritoneal carcinomatosis in gastric cancer
Despite advances in modern oncology, in Russia, 36% of gastric cancers are detected at an advanced stage, with a one-year mortality rate of 39.6%. One of the most common causes of death from gastric cancer is peritoneal carcinomatosis. Synchronous peritoneal carcinomatosis is diagnosed in 18–26% of cases. Metachronous carcinomatosis occurs in 7–39% of patients 8.5–26 months after the primary tumor is removed. To date, there are no effective treatments for peritoneal carcinomatosis. Tumors accompanied by peritoneal carcinomatosis are often resistant to systemic chemotherapy. Cytoreductive surgeries and intraperitoneal chemotherapy are not always possible or successful for all patients.This review focuses on analyzing the molecular and genetic mechanisms of peritoneal carcinomatosis in gastric cancer and presents an original hypothesis suggesting that peritoneal carcinomatosis occurs when tumor cells acquire the ability to autonomously exist in a matrix-independent state in the ascitic fluid without undergoing apoptosis (anoeucsis). Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, 10,025 scientific papers were identified, of which 228 English-language and 323 Russian-language publications met the analysis criteria. Twenty-nine articles (including four Russian-language ones) relevant to the topic of this review were included in the review. It is assumed that the identification of key molecules associated with the matrixindependent existence of tumor cells could serve as the basis for the development of technologies for predicting peritoneal carcinomatosis, as well as for the development of new targeted therapy for metastatic gastric cancer.
- 31 August 2023
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 63 (8) , 19-25
Clinical and Morphological Features of Myocardial Infarction in Patients With a New Coronavirus Infection COVID-19
Aim To analyze fatal outcomes of myocardial infarction (MI) in patients after COVID-19. Material and methods Data of pathoanatomical protocols and case histories of 612 patients managed in clinics of the Siberian State Medical University from 01.01.2020 through 31.12.2021 were studied. 68 (11%) of these patients were transferred to the clinics from respiratory hospitals for rehabilitation after the novel coronavirus infection. The main condition for hospitalization was a negative polymerase chain reaction (PCR) test for SARS-CoV-2 virus RNA. 544 (89%) of patients had no history of COVID-19. The incidence of MI was 14% (7/68) in patients after COVID-19 and 10% (74/544) in patients who have not had it. In pathoanatomical protocols and case histories of 81 patients diagnosed with MI, macroscopic and histological changes in the heart, pericardial cavity, coronary arteries, and laboratory results were evaluated. Statistical analysis was performed with a STATISTICA version 10.0 software package. Results The patients after COVID-19 had a lower percentage stenosis, more frequent coronary artery thrombosis, and a positive D-dimer. According to our data, MI emerged 10.0 (2.0; 21.0) days after admission to the hospital, had a larger area, always was transmural, and rapidly resulted in death; the time of necrotic changes in all cases did not exceed 24 h. Upon admission to the hospital, the PCR test for SARS-CoV-2 virus RNA was negative, and acute inflammatory changes were stopped at the previous stage of hospitalization. Conclusion The risk of coronary thrombosis in patients after COVID-19 remains after the relief of acute inflammatory response and elimination of the infectious agent, thereby creating a risk of MI, that often leads to a fatal outcome.
- 31 August 2023
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 63 (8) , 19-25
Clinical and Morphological Features of Myocardial Infarction in Patients With a New Coronavirus Infection COVID-19
Aim To analyze fatal outcomes of myocardial infarction (MI) in patients after COVID-19. Material and methods Data of pathoanatomical protocols and case histories of 612 patients managed in clinics of the Siberian State Medical University from 01.01.2020 through 31.12.2021 were studied. 68 (11%) of these patients were transferred to the clinics from respiratory hospitals for rehabilitation after the novel coronavirus infection. The main condition for hospitalization was a negative polymerase chain reaction (PCR) test for SARS-CoV-2 virus RNA. 544 (89%) of patients had no history of COVID-19. The incidence of MI was 14% (7/68) in patients after COVID-19 and 10% (74/544) in patients who have not had it. In pathoanatomical protocols and case histories of 81 patients diagnosed with MI, macroscopic and histological changes in the heart, pericardial cavity, coronary arteries, and laboratory results were evaluated. Statistical analysis was performed with a STATISTICA version 10.0 software package. Results The patients after COVID-19 had a lower percentage stenosis, more frequent coronary artery thrombosis, and a positive D-dimer. According to our data, MI emerged 10.0 (2.0; 21.0) days after admission to the hospital, had a larger area, always was transmural, and rapidly resulted in death; the time of necrotic changes in all cases did not exceed 24 h. Upon admission to the hospital, the PCR test for SARS-CoV-2 virus RNA was negative, and acute inflammatory changes were stopped at the previous stage of hospitalization. Conclusion The risk of coronary thrombosis in patients after COVID-19 remains after the relief of acute inflammatory response and elimination of the infectious agent, thereby creating a risk of MI, that often leads to a fatal outcome.